Guggenheim has initiated coverage on Celcuity Inc (CELC) with a Buy rating, marking the firm's first assessment of the biotechnology company. Headquartered in Minneapolis, Celcuity operates as a cellular analysis company focused on innovative cancer treatments. Its lead therapeutic candidate, gedatolisib, targets advanced breast cancer and metastatic castration-resistant prostate cancer.
As of September 21, 2025, Celcuity's stock trades at $98.17, with a market capitalization of $4.4 billion. The company's recent earnings performance has shown mixed results, with a Q3 2025 EPS of -$0.92, exceeding estimates by 10.6%. Upcoming earnings are scheduled for August 12, 2026, with EPS estimates at -$1.15 and revenue expectations of $765,000.
Analyst ratings and price targets are based on extensive research and financial models, providing insights into a company's investment potential. However, these ratings reflect assumptions that may not always materialize. Investors are encouraged to consider a range of factors, including company fundamentals and industry trends, when making decisions.
The latest rating from Guggenheim adds to a consensus that currently includes 6 Strong Buy, 8 Buy, and 1 Hold ratings among analysts. Such decisions reflect a broader confidence in Celcuity's growth prospects as it continues to develop its innovative therapies.